Ibandronate: A well-tolerated intravenous and oral treatment for metastatic bone disease

European Journal of Cancer, Supplement

Volumn 2, Issue 5, 2004, Pages 13-16

  Diel, I J ^a  

^a CGG Klinik GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ARTICLE; ASTHENIA; BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CYTOTOXICITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGITIS; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; HYDRONEPHROSIS; HYPOCALCEMIA; KIDNEY FAILURE; KIDNEY PAIN; METABOLIC DISORDER; MULTICENTER STUDY; MYALGIA; NAUSEA; NUTRITIONAL DISORDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 2442473451     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.01.004     Document Type: Article

References (21)

1. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br. J. Cancer. 55:1987;61-66
2. Coleman R.E. Skeletal complications of malignancy. Cancer. 80:(Suppl. 8):1997;1588-1594
3. Diel I.J., Solomayer E.-F., Bastert G. Treatment of metastatic bone disease in breast cancer bisphosphonates. Clin. Breast Cancer. 1:2000;43-51
4. Janjan N. Bone metastases: approaches to management. Semin. Oncol. 28:(Suppl. 11):2001;28-34
5. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. 18:2000;1378-1391
6. Pavlakis N., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 1:2002;CD003474
7. Body J.J., Bartl R., Burckhardt P., et al. Current use of bisphosphonates in oncology. J. Clin. Oncol. 16:1998;3890-3899
8. Hurst M., Noble S. Clodronate. A review of its use in breast cancer. Drugs Aging. 15:1999;143-167
9. Powles T., Paterson S., Kanis J., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 20:2002;3219-3224
10. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol. 28:2001;49-53
11. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 7:2001;377-387
12. Adami S., Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf. 14:1996;158-170
13. Bounameaux H.M., Schifferli J., Montani J.P., et al. Renal failure associated with intravenous disphosphonates. Lancet. 1:1983;471
14. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14:2003;1399-1405
15. Diel I.J., Body J.J., Tripathy D., Bergstrom B. Oral daily ibandronate in women with metastatic breast cancer a pooled safety analysis. Proc ASCO. 22:2003;47. (abstr. 186)
16. Body J.J. Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease. EJC Supplements. 2:(5):2004;. this issue (doi: 10.1016/j.ejcsup.2004.01.002)
17. Johnson K.B., Gable P., Kaime E.M., et al. Significant deterioration in renal function with the new bisphosphonate, zoledronic acid. Proc. ASCO. 22:2003;738. (abstr 2968)
18. Markowitz G.S., Fine P.L., Stack J.I., et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 64:2003;281-289
19. Banerjee D., Asif A., Striker L., et al. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis. 41:2003;E18
20. Kloth D.D., McDermott R.S., Rogatko A., Langer C.J. Impact of zoledronic acid (Zol) on renal function in patients (pts) with cancer as constant monitoring necessary? Proc. ASCO. 22:2003;755. (abstr 3036)
21. Zometa®. Prescribing Information. Novartis.